Silk Fibroin Based Formulations as Potential Hemostatic Agents
Silk Fibroin Based Formulations as Potential Hemostatic Agents
复制标题
DOI：
10.1021/acsbiomaterials.2c00170
复制
发表时间：
2022-06-13
影响因子：
5.8
通讯作者：
Mandal, Biman B.
中科院分区：
文献类型：
--
作者：
Biswas, Saptarshi;Bhunia, Bibhas K.;Mandal, Biman B.
有效的出血控制对于国防领域和平民创伤中危及生命的紧急情况是必不可少的。在严重损伤期间，外部应用止血剂以模拟和加速自然止血过程。市售的局部止血剂具有几个局限性，例如，烧灼感、坏死，严重损伤无效，产品成本高。在本研究中，我们开发了丝素蛋白纤维为基础的配方，并评估其作为一种具有成本效益的潜在止血剂，缩短凝血时间。在碱水解过程之后产生基于丝纤维的粉末，其中用随机切碎丝微纤维的氢氧化钠（NaOH）溶液处理桑蚕丝纤蛋白纤维。物理化学反应参数，例如，优化反应温度、NaOH溶液的摩尔浓度和温育时间以获得最大的微纤维产率。采用场发射扫描电镜和X射线能谱仪对碱水解蚕丝微纤维的表面性质进行了分析。分析AHSMf的吸水能力以及血液凝固过程中pH和温度（类似于30 ℃）的变化。此外，使用山羊和人血通过体外全血凝血试验评价AHSMf的止血潜力。体外研究表明，与丝水凝胶粉末（不含NaOH）相比，在AHSMf存在下，凝血时间（CT = 20-30 s）、凝血酶原时间（PT =类似于27%）和活化部分凝血活酶时间（APTT =类似于14%）缩短。因此，开发的AHSMf可能是一种有前途的材料，作为一个潜在的止血剂。
Effective hemorrhage control is indispensable for life-threatening emergencies in defense fields and civilian trauma. During major injuries, hemostatic agents are applied externally to mimic and accelerate the natural hemostasis process. Commercially available topical hemostatic agents are associated with several limitations, e.g., burning sensation, necrosis, futile in severe injuries, and high costs of the products. In the present study, we developed silk fibroin fiber-based formulations and evaluated their use as a cost-effective potential hemostatic agent with shortened clotting time. Silk fiber-based powder was produced following the alkaline hydrolysis process, wherein Bombyx mori silk fibroin fibers were treated with sodium hydroxide (NaOH) solution that randomly chopped the silk microfibers. Physicochemical reaction parameters, e.g., reaction temperature, molarity of NaOH solution, and incubation time, were optimized to achieve the maximum yield of microfibers. The surface properties of alkaline hydrolyzed silk microfibers (AHSMf) were analyzed by field emission scanning electron microscopy and energy dispersive X-ray studies. The water uptake capacity of AHSMf and the change in pH and temperature (similar to 30 degrees C) during blood clotting were analyzed. Further, the hemostatic potential of AHSMf was evaluated by an in vitro whole blood clotting assay using both goat and human blood. The in vitro studies demonstrated a reduced blood clotting time (CT = 20-30 s), prothrombin time (PT = similar to 27%), and activated partial thromboplastin time (APTT = similar to 14%) in the presence of AHSMf when compared to silk hydrogel powder (devoid of NaOH). Thus, the developed AHSMf could be a promising material to serve as a potential hemostatic agent.